Celldex Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Celldex Therapeutics

09/11/2022 21:40

* Celldex Therapeutics Inc  CLDX.OQ  reported a quarterly
adjusted
loss of 57 cents​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of 58 cents per share.
    * Revenue rose 166% to $407.00 thousand from a year ago;
analysts
expected $360.00 thousand. 
    * Celldex Therapeutics Inc's reported EPS for the quarter
was a
loss of 57 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Celldex Therapeutics Inc shares had risen by 22.9% this
quarter and lost 10.6% so far this year.
    * The company reported a quarterly loss of $26.78 million.
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $65.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 09:40 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.58          -0.57          Beat
 Jun. 30 2022      -0.51          -0.59          Missed
 Mar. 31 2022      -0.45          -0.49          Missed
 Dec. 31 2021      -0.42          -0.43          Missed